121 related articles for article (PubMed ID: 15704674)
21. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.
Sundbäck M; Douagi I; Dayaraj C; Forsell MN; Nordström EK; McInerney GM; Spångberg K; Tjäder L; Bonin E; Sundström M; Liljeström P; Karlsson Hedestam GB
Virology; 2005 Oct; 341(2):190-202. PubMed ID: 16098555
[TBL] [Abstract][Full Text] [Related]
22. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy.
Babudieri S; Longo B; Sarmati L; Starnini G; Dori L; Suligoi B; Carbonara S; Monarca R; Quercia G; Florenzano G; Novati S; Sardu A; Iovinella V; Casti A; Romano A; Uccella I; Maida I; Brunetti B; Mura MS; Andreoni M; Rezza G
J Med Virol; 2005 Jul; 76(3):311-7. PubMed ID: 15902712
[TBL] [Abstract][Full Text] [Related]
23. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
[TBL] [Abstract][Full Text] [Related]
24. The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?
Sheppard N; Sattentau Q
Expert Rev Mol Med; 2005 Feb; 7(2):1-21. PubMed ID: 15710051
[TBL] [Abstract][Full Text] [Related]
25. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
Devi KhS; Brajachand N; Singh HL; Singh YM
J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
[TBL] [Abstract][Full Text] [Related]
26. Fc receptor but not complement binding is important in antibody protection against HIV.
Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
[TBL] [Abstract][Full Text] [Related]
27. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India.
Kumar S; Aggarwal P; Vajpayee M; Pandey RM; Seth P
Vaccine; 2006 Mar; 24(14):2585-93. PubMed ID: 16480792
[TBL] [Abstract][Full Text] [Related]
28. Population effects of preventive and therapeutic HIV vaccines in early- and late-stage epidemics.
Owens DK; Edwards DM; Shachter RD
AIDS; 1998 Jun; 12(9):1057-66. PubMed ID: 9662203
[TBL] [Abstract][Full Text] [Related]
29. Risks of seroconversion of hepatitis B, hepatitis C and human immunodeficiency viruses in children with multitransfused thalassaemia major.
Lee WS; Teh CM; Chan LL
J Paediatr Child Health; 2005; 41(5-6):265-8. PubMed ID: 15953326
[TBL] [Abstract][Full Text] [Related]
30. A safe, effective and affordable HIV vaccine--an urgent global need.
Joseph J; Etcheverry F; Alcami J; María GJ
AIDS Rev; 2005; 7(3):131-8. PubMed ID: 16302460
[TBL] [Abstract][Full Text] [Related]
31. Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines.
Koff WC; Russell ND; Walport M; Feinberg MB; Shiver JW; Karim SA; Walker BD; McGlynn MG; Nweneka CV; Nabel GJ
Vaccine; 2013 Apr; 31 Suppl 2():B204-8. PubMed ID: 23598483
[TBL] [Abstract][Full Text] [Related]
32. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients.
Kumar R; Singla V; Kacharya Sk
Trop Gastroenterol; 2008; 29(3):136-47. PubMed ID: 19115605
[TBL] [Abstract][Full Text] [Related]
33. Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis.
Collenberg E; Ouedraogo T; Ganamé J; Fickenscher H; Kynast-Wolf G; Becher H; Kouyaté B; Kräusslich HG; Sangaré L; Tebit DM
J Med Virol; 2006 May; 78(5):683-92. PubMed ID: 16555290
[TBL] [Abstract][Full Text] [Related]
34. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
35. Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis.
Martín-Carbonero L; Barreiro P; Jiménez-Galán G; García-Berriguete R; Núñez M; Ríos P; González-Lahoz J; Soriano V
J Viral Hepat; 2007 Jun; 14(6):392-5. PubMed ID: 17501759
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels.
Assal A; Barlet V; Deschaseaux M; Dupont I; Gallian P; Guitton C; Morel P; van Drimmelen H; David B; Lelie N; De Micco P
Transfusion; 2009 Feb; 49(2):301-10. PubMed ID: 19389212
[TBL] [Abstract][Full Text] [Related]
37. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
38. [Therapeutic and preventive vaccine against HIV problems and the necessity to develop one].
García F
Rev Enferm; 2005 Dec; 28(12):24-8. PubMed ID: 16459877
[TBL] [Abstract][Full Text] [Related]
39. HIV vaccine development.
Johnston MI
Dev Biol (Basel); 2002; 110():57-63. PubMed ID: 12477307
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic immunization strategies for the control of HIV-1.
Dorrell L
Expert Rev Vaccines; 2005 Aug; 4(4):513-20. PubMed ID: 16117708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
